Chemotherapie-freie Behandlung der CLL

Die Therapielandschaft der chronischen lymphatischen Leukämie (CLL) hat sich in den letzten Jahren dramatisch verändert. Aus der Vielfalt neuer Angriffspunkte ergibt sich die Frage, inwieweit Chemo-Immuntherapie (CIT) als bisheriges Rückgrat der CLL-Therapie vor allem in der Erstlinie sinnvoll durch neue zielgerichtete Behandlungsansätze ersetzt werden kann.

• Literatur

• 1 Catovsky D, Richards S, Matutes E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239
• 2 Fischer K, Bahlo J, Fink AM. et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208-215
• 3 Eichhorst B, Fink AM, Bahlo J. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928-942
• 4 Goede V, Fischer K, Busch R. et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 2013; 27: 1172-1174
• 5 Goede V, Fischer K, Engelke A. et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015; 29: 1602-1604
• 6 Thompson PA, Tam CS, O'Brien SM. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303-309
• 7 Bottcher S, Ritgen M, Fischer K. et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988
• 8 Byrd JC, Furman RR, Coutre SE. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42
• 9 Farooqui MZ, Valdez J, Martyr S. et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015; 16: 169-176
• 10 Burger JA, Tedeschi A, Barr PM. et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373: 2425-2437
• 11 Moreno C, Greil R, Demirkan F. et al. Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Blood 2018; 132: 691
• 12 Woyach JA, Ruppert AS, Heerema NA. et al. Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood 2018; 132: 6
• 13 Shanafelt TD, Wang V, Kay NE. et al. A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood 2018; 132: LBA-4
• 14 Byrd JC, Brown JR, O'Brien S. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223
• 15 Seymour JF, Kipps TJ, Eichhorst B. et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378: 1107-1120
• 16 Mato AR, Hill BT, Lamanna N. et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2017; 28: 1050-1056
• 17 Jones JA, Mato AR, Wierda WG. et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19: 65-75
• 18 O'Brien S, Furman RR, Coutre S. et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018; 131: 1910-1919